ATE501151T1 - Substituierte pyrano ä2, 3 - büpyridinderivate als cannabinoid-1 rezeptormodulatoren - Google Patents
Substituierte pyrano ä2, 3 - büpyridinderivate als cannabinoid-1 rezeptormodulatorenInfo
- Publication number
- ATE501151T1 ATE501151T1 AT08713287T AT08713287T ATE501151T1 AT E501151 T1 ATE501151 T1 AT E501151T1 AT 08713287 T AT08713287 T AT 08713287T AT 08713287 T AT08713287 T AT 08713287T AT E501151 T1 ATE501151 T1 AT E501151T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- disorders
- disease
- useful
- compounds
- Prior art date
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 206010014612 Encephalitis viral Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 abstract 1
- 206010019196 Head injury Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010062519 Poor quality sleep Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 208000014797 chronic intestinal pseudoobstruction Diseases 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 201000002498 viral encephalitis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89860207P | 2007-01-31 | 2007-01-31 | |
| US90569007P | 2007-03-08 | 2007-03-08 | |
| PCT/US2008/001042 WO2008094476A1 (en) | 2007-01-31 | 2008-01-25 | Substituted pyrano [2, 3 - b] pyridine derivatives as cannabinoid -1 receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE501151T1 true ATE501151T1 (de) | 2011-03-15 |
Family
ID=39371009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08713287T ATE501151T1 (de) | 2007-01-31 | 2008-01-25 | Substituierte pyrano ä2, 3 - büpyridinderivate als cannabinoid-1 rezeptormodulatoren |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7999107B2 (de) |
| EP (1) | EP2109615B1 (de) |
| JP (1) | JP2010516810A (de) |
| AT (1) | ATE501151T1 (de) |
| AU (1) | AU2008211259A1 (de) |
| CA (1) | CA2676167A1 (de) |
| DE (1) | DE602008005405D1 (de) |
| WO (1) | WO2008094476A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080279846A1 (en) * | 2007-05-11 | 2008-11-13 | Thomas Jefferson University | Methods of treatment and prevention of neurodegenerative diseases and disorders |
| KR101119719B1 (ko) | 2009-06-15 | 2012-03-09 | 경희대학교 산학협력단 | 피라노피란-1,8-다이온을 함유하는 천식치료제 |
| US8962627B2 (en) * | 2009-10-30 | 2015-02-24 | Prestwick Chemical, Inc. | Oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| GB0922589D0 (en) * | 2009-12-23 | 2010-02-10 | Almac Discovery Ltd | Pharmaceutical compounds |
| KR101326557B1 (ko) * | 2011-03-31 | 2013-11-08 | 주식회사종근당 | 카나비노이드 수용체〔ｃｂｉ〕길항제로서의 벤즈아미드 유도체 |
| WO2013040324A1 (en) | 2011-09-16 | 2013-03-21 | Galectin Therapeutics, Inc. | Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease |
| ES2848538T3 (es) | 2012-06-06 | 2021-08-10 | Galectin Therapeutics Inc | Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible |
| EP3133065A1 (de) | 2015-08-21 | 2017-02-22 | Merck Patent GmbH | Verbindungen für optisch aktive vorrichtungen |
| DK3354649T3 (da) * | 2015-10-15 | 2020-02-24 | Jiangsu Hengrui Medicine Co | Oxaspiroderivat, fremstillingsmetode derfor og anvendelser deraf i lægemidler |
| EP3363786A1 (de) | 2017-02-15 | 2018-08-22 | Merck Patent GmbH | Verbindungen für optisch aktive vorrichtungen |
| EP3363793A1 (de) | 2017-02-15 | 2018-08-22 | Merck Patent GmbH | Hydrophobe verbindungen zur herstellung von optisch aktiven vorrichtungen |
| US10897925B2 (en) | 2018-07-27 | 2021-01-26 | Joseph Pandolfino | Articles and formulations for smoking products and vaporizers |
| US20200035118A1 (en) | 2018-07-27 | 2020-01-30 | Joseph Pandolfino | Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes |
| JP7673982B2 (ja) * | 2019-10-02 | 2025-05-09 | ドメイン・セラピューティクス | プロスタグランジンｅ２（ｐｇｅ２）ｅｐ４受容体アンタゴニスト |
| EP4153598A1 (de) | 2020-05-20 | 2023-03-29 | AMO Ireland | Azacoumarin- und azathiocoumarinderivate zur verwendung in optisch aktiven vorrichtungen |
| GB2600384A (en) | 2020-09-30 | 2022-05-04 | Vaderis Therapeutics Ag | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
| WO2022128050A1 (en) | 2020-12-14 | 2022-06-23 | Symrise Ag | Medicament for fighting inflammation and pain |
| AR127618A1 (es) | 2021-11-29 | 2024-02-14 | Bayer Ag | Dihidropiranopiridinas sustituidas, sales o n-óxidos de las mismas y su uso como sustancias herbicidamente activas |
| WO2023114539A1 (en) * | 2021-12-17 | 2023-06-22 | Pretzel Therapeutics, Inc. | Amino chromen-2-one modulators of polrmt |
| CN115260092B (zh) * | 2022-08-23 | 2023-08-25 | 山东京博生物科技有限公司 | 一种2-氯烟酰胺及其n取代衍生物的合成方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3630200A (en) | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US5140031A (en) | 1989-05-31 | 1992-08-18 | E. R. Squibb & Sons, Inc. | Pyranyl cyanoguanidine derivatives |
| US5061813A (en) | 1990-04-02 | 1991-10-29 | E. R. Squibb & Sons, Inc. | Substituted cyanoimino benzopyranes |
| GB9102804D0 (en) | 1991-02-11 | 1991-03-27 | Ici Plc | Heterocyclic derivatives |
| JPH04282353A (ja) | 1991-03-11 | 1992-10-07 | Yoshitomi Pharmaceut Ind Ltd | ベンゾピラン類縁体 |
| JP2647762B2 (ja) | 1991-07-30 | 1997-08-27 | 吉富製薬株式会社 | ベンゾピラン類縁体 |
| US5463059A (en) | 1992-11-10 | 1995-10-31 | E. R. Squibb & Sons, Inc. | Process for the preparation of intermediates useful in the preparation of pyranyl cyanoguanidine derivatives |
| IL109229A0 (en) | 1993-05-11 | 1994-07-31 | Bristol Myers Squibb Co | Heterocyclic compounds and processes for the preparation of pyranyl cyanoguanidine derivatives using the same |
| JPH10501256A (ja) | 1994-06-10 | 1998-02-03 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Ｃ−４アミド置換化合物およびその治療剤としての使用 |
| WO1998009969A1 (en) | 1996-09-05 | 1998-03-12 | Astra Pharmaceuticals Ltd. | Novel aryl-pyridazines |
| AR013184A1 (es) | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| EP0895994A3 (de) | 1997-08-05 | 1999-12-15 | Hoechst Marion Roussel Deutschland GmbH | Sulfonamid-substituierte Pyranopyridine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| GB9914255D0 (en) | 1999-06-18 | 1999-08-18 | Lilly Forschung Gmbh | Pharmaceutical compounds |
| CA2395795A1 (en) | 2000-01-03 | 2001-07-12 | Pharmacia Corporation | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders |
| US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| JO2352B1 (en) | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Compounds for the treatment of non-adaptation of the bottom of the uterus |
| CA2433158C (en) | 2000-12-28 | 2011-05-10 | Shionogi & Co., Ltd. | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor |
| US20040259909A1 (en) | 2001-10-16 | 2004-12-23 | Mccarthy Dennis | Treatment of fibromyalgia syndrome |
| RU2325387C2 (ru) | 2001-12-21 | 2008-05-27 | Анормед Инк. | Гетероциклические соединения с повышенной эффективностью, связывающиеся с рецептором хемокина |
| US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| CA2478183C (en) | 2002-03-12 | 2010-02-16 | Merck & Co. Inc. | Substituted amides |
| JP4667867B2 (ja) * | 2002-08-02 | 2011-04-13 | メルク・シャープ・エンド・ドーム・コーポレイション | 置換フロ［２，３−ｂ］ピリジン誘導体 |
| JP4282353B2 (ja) | 2003-03-27 | 2009-06-17 | シチズンセイミツ株式会社 | 時計用文字板 |
| US7183413B2 (en) | 2003-04-11 | 2007-02-27 | Taigen Biotechnology | Aminoquinoline compounds |
| JP3939744B2 (ja) | 2003-06-11 | 2007-07-04 | メルク エンド カムパニー インコーポレーテッド | 置換３−アルキルおよび３−アルケニルアゼチジン誘導体 |
| US20050129610A1 (en) | 2003-06-24 | 2005-06-16 | Johns Hopkins University | Imaging agents and methods of imaging alpha7-nicotinic cholinergic receptor |
| EP1670456A2 (de) | 2003-10-06 | 2006-06-21 | Cytokinetics, Inc. | Verbindungen, zusammensetzungen und verfahren |
| US7728141B2 (en) | 2003-11-04 | 2010-06-01 | Merck Sharp & Dohme Corp. | Substituted naphthyridinone derivatives |
| WO2006045096A2 (en) | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases |
| TW200838516A (en) * | 2007-01-31 | 2008-10-01 | Merck & Co Inc | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
-
2008
- 2008-01-16 US US12/009,114 patent/US7999107B2/en not_active Expired - Fee Related
- 2008-01-25 DE DE602008005405T patent/DE602008005405D1/de active Active
- 2008-01-25 JP JP2009548272A patent/JP2010516810A/ja not_active Withdrawn
- 2008-01-25 WO PCT/US2008/001042 patent/WO2008094476A1/en not_active Ceased
- 2008-01-25 AT AT08713287T patent/ATE501151T1/de not_active IP Right Cessation
- 2008-01-25 CA CA002676167A patent/CA2676167A1/en not_active Abandoned
- 2008-01-25 EP EP08713287A patent/EP2109615B1/de not_active Not-in-force
- 2008-01-25 AU AU2008211259A patent/AU2008211259A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010516810A (ja) | 2010-05-20 |
| DE602008005405D1 (de) | 2011-04-21 |
| EP2109615B1 (de) | 2011-03-09 |
| US7999107B2 (en) | 2011-08-16 |
| WO2008094476A1 (en) | 2008-08-07 |
| AU2008211259A1 (en) | 2008-08-07 |
| CA2676167A1 (en) | 2008-08-07 |
| EP2109615A1 (de) | 2009-10-21 |
| US20080207666A1 (en) | 2008-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE501151T1 (de) | Substituierte pyrano ä2, 3 - büpyridinderivate als cannabinoid-1 rezeptormodulatoren | |
| WO2008024284A3 (en) | Sulfonylated piperazines as cannabinoid-1 receptor modulators | |
| WO2007136607A3 (en) | Substituted esters as cannabinoid-1 receptor modulators | |
| ATE375349T1 (de) | Substituierte furo(2,3-b)pyridin derivate | |
| MXPA05013583A (es) | Derivados de 3-alquil y 3-alquenilazetidina sustituidos. | |
| DE60334787D1 (de) | Substituierte amide | |
| EP1492784A4 (de) | Substituierte 2,3-diphenylpyridine | |
| WO2003082190A3 (en) | Spirocyclic amides as cannabinoid receptor modulators | |
| JO2482B1 (en) | Amide compounds by replacement | |
| WO2004058145A3 (en) | Substituted amides | |
| WO2003063781A3 (en) | Substituted imidazoles as cannabinoid receptor modulators | |
| WO2004029204A3 (en) | Substituted pyrimidines | |
| ATE452890T1 (de) | Substituierte naphthyridinonderivate | |
| WO2003086288A3 (en) | Bicyclic amides | |
| WO2005027837A3 (en) | Substituted sulfonamides | |
| WO2003007887A3 (en) | Substituted imidazoles as cannabinoid receptor modulators | |
| NO20063381L (no) | CB1 modulatorforbindelser | |
| ECSP088477A (es) | Derivados de 3-alquilazetidina sustituidos con heterociclos | |
| MX2021001379A (es) | Compuestos de 1-metil-4-[(4-fenilfenil)sulfonilmetil]ciclohexanol y 1-metil-4-[[4-(2-piridil)fenil]sulfonilmetil]ciclohexanol y su uso terapeutico. | |
| WO2007064566A3 (en) | Heterocycle-substituted 3-alkyl azetidine derivatives | |
| CN107735401A (zh) | 取代二氢吡咯并吡唑衍生物 | |
| ATE457985T1 (de) | Substituierte pyrazinonderivate zur verwendung als arzneimittel | |
| JP2020503332A5 (de) | ||
| WO2006041797A3 (en) | Acyclic hydrazides as cannabinoid receptor modulators | |
| TH90245A (th) | อนุพันธ์ของ 3- อัลคิลอาเซตติดินที่ถูกแทนที่ด้วยเฮทเทอร์โรไซเคิล |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |